NKGen Biotech AAQS

Mitä NKGen Biotech tekee? NKGen Biotech Inc, listed under the ticker NKGN with ISIN US65488A1016, is a US-based biotechnology company headquartered in Santa Ana, California. The company went public via an IPO on May 21, 2021. NKGen Biotech operates as a clinical-stage biotechnology firm focused on developing and commercializing natural killer (NK) cell therapies for the treatment of neurodegenerative and oncological diseases. The company utilizes a platform called SuperNK, which involves the use of autologous and allogeneic NK cell therapies. The SuperNK platform, referred to as SNK (super-activated), entails harvesting pure NK cells from a patient’s blood, activating them, and infusing them back into the patient’s body. This process aims to enhance immune system function, eliminate diseased or abnormal cells, and prevent disease recurrence. NKGen Biotech is advancing clinical trials for its SNK01 therapy targeting neurodegenerative diseases and SNK02 therapy for cancer patients. The company’s approach leverages autologous NK cell immunotherapy, which uses the patient’s own immune cells to provide immune enhancement. NKGen Biotech’s therapies are designed to address conditions including cancer, autoimmune disorders, and neurodegenerative diseases. The company’s website is https://nkgenbiotech.com/. NKGen Biotech on yksi Eurpooliin suosituimmista yhtiöistä.